All4Nutra
Introduction
Revolutionizing Pain Relief for Rheumatoid Arthritis (RA)
Lornoxicam, a potent NSAID, is widely used for rapid pain relief in rheumatoid arthritis. However, its poor water solubility (BCS II) and bitter taste have historically limited its effectiveness in fast disintegrating tablet (FDT) formulations.
Recent advances using F-MELT®, by Fuji Chemical Industries, and optimized superdisintegrant strategies have transformed the landscape, enabling rapid onset, improved patient compliance, and superior bioavailability.
F-MELT®: The Game-Changer int FDT Technologoy
What is F-MELT® ?
F-MELT® is a co-processed excipient specifically designed for fast disintegration and dissolution in oral solid dosage forms. It combines multiple functional ingredients to deliver:
- Ultra-fast disintegration
- Excellent mouthfeel
- Superior compressibility
- Enhanced stability
Why F-MELT® for Lornoxicam FDTs?
In the referenced study (Moutasim et al., 2017b), F-MELT® Type C was pivotal in achieving a disintegration time as low as 13.37 seconds in vivo and 18 seconds in vitro for the optimized lornoxicam FDT (Formula F2) (Containing 20% of drug complex, 73.67% of F-MELT® Type C, 4.17% of Crospovidone, 0.83% of Monoammonium glycyrrhizinate, 1% of Menthol, and 0.33% of magnesium stearate). This rapid breakdown ensures that drug is quickly available for absorption, providing fast pain relief.
Formulation Highlights: Lornoxicam FDTs with F-MELT®
Key Ingredients in Optimized Formula (F2)
Performance Metrics
- Disintegration Time:
13 sec. (in vivo), 18 sec. (in vitro) - Dissolution:
95.9% drug release in 6 minutes - Bioavailability:
105.49% relative to reference (Zeficam®) - Palatability:
Rated as highly acceptable by volunteers
Study Insights
The combination of F-MELT® Type C and crospovidone in F2 resulted in the shortest disintegration and highest dissolution rates among all tested formulations. This synergy is essential for drugs like lornoxicam, where rapid onset is crucial.
Why Choose F-MELT® Lornoxicam FDTS?
Fastest Onset of Action:
Ideal for acute pain management in RA and postoperative settings
Bioequivalent to Marketed Brands:
Demonstrated comparable or superior pharmacokinetics to Zeficam®.
Superior Patient Compliance:
No water needed, pleasant taste, and easy administration for all age groups.
Palatability and Acceptance:
Volunteers rated the lornoxicam FDTs containing F-MELT® type C as highly palatable, overcoming the bitterness challenge.
Conclusion
Setting a New Standard in Fast Disintegrating Tablets
F-MELT®-based lornoxicam FDTs represent a significant advancement in oral drug delivery, offering rapid disintegration, enhanced dissolution, and improved patient satisfaction. The strategic use of platform technologies such as F-MELT® is key to unlocking these benefits, making this formulation a compelling choice for both patients and healthcare providers.
Continue reading and see the full Pharmaceutical Technical Newsletter on Dissolve Pain in Seconds: The Advantage of F-MELT®in Lornoxicam Fast Disintegrating Tablets here:
(click the picture to download the technical newsletter)
Source: Fuji Chemical Industries technical newsletter Dissolve Pain in Seconds: The Advantage of F-MELT®in Lornoxicam Fast Disintegrating Tablets
Read also the other Technical Newsletter of Fuji Chemical Industries here:
- Special Issue – Mitigating Nitrosamine Risks in Drug Products
- Special Issue – Neusilin Redefining Silica´s Potential in Solid Oral Dosage Forms
- Special Issue – The Potential for a Ban on TiO2 (E171) use in Pharmaceuticals
- Special Issue – pH Independent Bi-layer Self-microemulsifying Tablets (SMETs) of Candesartan Cilexetil with Fujicalin® and Neusilin®
- Issue 1, 2025 – Revolutionizing Axitinib Delivery with Liquisolid Technology
